1-4 of 4
Ronan Swords, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, MBBS, MHS, Daniel A Pollyea, MD, Jacqueline S Garcia, MD, Andrew Brunner, MD, Fernando Roncolato, BMed, FRACP, FRCPA, Uma Borate, MD, Olatoyosi Odenike, MD, Ashish R. Bajel, FRACP, Anne Marie Watson, FRACP, FRCPA, MBBS, Katharina Götze, Florian Nolte, MD, Peter T. Tan, MBBS, Wan-Jen Hong, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Lori Gressick, BS, William Ainsworth, PhD, Jason Harb, PhD, Ahmed Hamed Salem, PhD FCP, John Hayslip, Ronan Swords, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 565.
https://doi.org/10.1182/blood-2019-124994
Published: 2019
Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Naseema Gangat, MBBS, Brady Lee Stein, MD, Christian Marinaccio, Ronan Swords, MD PhD, Justin M. Watts, MD, Sandeep Gurbuxani, Olga Frankfurt, MD, Jessica K. Altman, MD, Jeremy Q. Wen, MD PhD, Noushin Farnoud, PhD, Christopher Famulare, MS, Akshar Patel, BA, Roberto Tapia, BS, Amy Handlogten, Yvonne Trang Dinh, BS, Kristen Englund, Shradha Patel, Juan Carlos Nobrega, Dalissa Tejera, MSN, Amber Thomassen, Harald Stein, MD PhD Dr. h.c., Juehua Gao, MD PhD, Peng Ji, MDPhD, Raajit K. Rampal, MD PhD, Francis J. Giles, MD FRCPI, FRCPath, Ayalew Tefferi, MD, John D. Crispino, PhD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 688.
https://doi.org/10.1182/blood-2018-99-110381
Published: 2018
Journal Articles

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Justin M Watts, MD, Terrence J Bradley, MD, Amber Thomassen, MA, MSN, Yvonne Trang Dinh, BS, Dalissa Tejera, MSN, Kristen Englund, Sorab Boga, MPH, Randy Astaiza, BS, Charles J Chen, MPH, Malika Abdur-Rahman, BS, MSED, Marinescu Ion, CCRC, FMG, Aymee Perez, PhD, Masoumeh Tayari, PhD, Lluis Morey, PhD, Maria E. Figueroa, MD, Ramin Shiekhattar, PhD, Arthur Zelent, PhD, Ronan Swords, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2721.
https://doi.org/10.1182/blood-2018-99-115411
Published: 2018
Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD
Journal: Blood
Blood (2014) 124 (21): 4809.
https://doi.org/10.1182/blood.V124.21.4809.4809
Published: 2014